Cargando…

Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity

Galectins have diverse functions and are involved in many biological processes because of their complex intra- and extracellular activities. Selective and potent inhibitors for galectins will be valuable tools to investigate the biological functions of these proteins. Therefore, we describe here the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao, Ippel, Hans, Miller, Michelle C., Wong, Tse J., Griffioen, Arjan W., Mayo, Kevin H., Pieters, Roland J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612729/
https://www.ncbi.nlm.nih.gov/pubmed/34912566
http://dx.doi.org/10.1039/c9qo00810a
_version_ 1784603503545548800
author Zhang, Hao
Ippel, Hans
Miller, Michelle C.
Wong, Tse J.
Griffioen, Arjan W.
Mayo, Kevin H.
Pieters, Roland J.
author_facet Zhang, Hao
Ippel, Hans
Miller, Michelle C.
Wong, Tse J.
Griffioen, Arjan W.
Mayo, Kevin H.
Pieters, Roland J.
author_sort Zhang, Hao
collection PubMed
description Galectins have diverse functions and are involved in many biological processes because of their complex intra- and extracellular activities. Selective and potent inhibitors for galectins will be valuable tools to investigate the biological functions of these proteins. Therefore, we describe here the synthesis of galectin inhibitors with a potential “chelate effect”. These compounds are designed to bind to two different binding sites on galectins simultaneously. In this paper a series of asymmetric “hybrid” compounds are prepared, which combine two galectin ligands (1) a substituted thiodigalactoside derivative and (2) an antagonist calixarene-based therapeutic agent. NMR spectroscopy was used to evaluate the interactions of these compounds with Galectin-1 and -3. In addition, cellular experiments were conducted to compare the cytotoxic effects of the hybrids with those of a calixarene derivative. While only the thiodigalactoside part of the hybrids showed strong binding, the calixarene part was responsible for observed cytoxoxicity effects, suggesting that the calixarene moiety may also be addressing a non-galectin target.
format Online
Article
Text
id pubmed-8612729
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-86127292021-12-13 Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity Zhang, Hao Ippel, Hans Miller, Michelle C. Wong, Tse J. Griffioen, Arjan W. Mayo, Kevin H. Pieters, Roland J. Org Chem Front Chemistry Galectins have diverse functions and are involved in many biological processes because of their complex intra- and extracellular activities. Selective and potent inhibitors for galectins will be valuable tools to investigate the biological functions of these proteins. Therefore, we describe here the synthesis of galectin inhibitors with a potential “chelate effect”. These compounds are designed to bind to two different binding sites on galectins simultaneously. In this paper a series of asymmetric “hybrid” compounds are prepared, which combine two galectin ligands (1) a substituted thiodigalactoside derivative and (2) an antagonist calixarene-based therapeutic agent. NMR spectroscopy was used to evaluate the interactions of these compounds with Galectin-1 and -3. In addition, cellular experiments were conducted to compare the cytotoxic effects of the hybrids with those of a calixarene derivative. While only the thiodigalactoside part of the hybrids showed strong binding, the calixarene part was responsible for observed cytoxoxicity effects, suggesting that the calixarene moiety may also be addressing a non-galectin target. The Royal Society of Chemistry 2019-07-12 /pmc/articles/PMC8612729/ /pubmed/34912566 http://dx.doi.org/10.1039/c9qo00810a Text en This journal is © the Partner Organisations https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Zhang, Hao
Ippel, Hans
Miller, Michelle C.
Wong, Tse J.
Griffioen, Arjan W.
Mayo, Kevin H.
Pieters, Roland J.
Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity
title Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity
title_full Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity
title_fullStr Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity
title_full_unstemmed Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity
title_short Hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity
title_sort hybrid ligands with calixarene and thiodigalactoside groups: galectin binding and cytotoxicity
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612729/
https://www.ncbi.nlm.nih.gov/pubmed/34912566
http://dx.doi.org/10.1039/c9qo00810a
work_keys_str_mv AT zhanghao hybridligandswithcalixareneandthiodigalactosidegroupsgalectinbindingandcytotoxicity
AT ippelhans hybridligandswithcalixareneandthiodigalactosidegroupsgalectinbindingandcytotoxicity
AT millermichellec hybridligandswithcalixareneandthiodigalactosidegroupsgalectinbindingandcytotoxicity
AT wongtsej hybridligandswithcalixareneandthiodigalactosidegroupsgalectinbindingandcytotoxicity
AT griffioenarjanw hybridligandswithcalixareneandthiodigalactosidegroupsgalectinbindingandcytotoxicity
AT mayokevinh hybridligandswithcalixareneandthiodigalactosidegroupsgalectinbindingandcytotoxicity
AT pietersrolandj hybridligandswithcalixareneandthiodigalactosidegroupsgalectinbindingandcytotoxicity